Abstract
Twenty-seven patients with disseminated malignant melanoma were treated monthly with cisplatin (CDDP) 120 mg m-2 on day 1, vindesine (VDS) 3 mg m-2 on day 2 and dacarbazine (DTIC) 250 mg m-2 on days 2-6. None of them had received prior chemotherapy. All patients are evaluable for response and toxicity. There were five (19%) complete (CR) and seven (26%) partial (PR) responses for a total response rate of 45%. We conclude that the combination of DTIC, VDS and CDDP is capable of producing a relatively high rate of response in patients with advanced metastatic malignant melanoma, but responses are short.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pectasides, D., Yianniotis, H., Alevizakos, N. et al. Treatment of metastatic malignant melanoma with dacarbazine, vindesine and cisplatin. Br J Cancer 60, 627–629 (1989). https://doi.org/10.1038/bjc.1989.327
Issue Date:
DOI: https://doi.org/10.1038/bjc.1989.327
This article is cited by
-
Development of drugs based on imidazole and benzimidazole bioactive heterocycles: recent advances and future directions
Medicinal Chemistry Research (2016)
-
Standards und Trends bei der Behandlung des malignen Melanoms
Onkopipeline (2009)
-
Kutanes Melanom
Der Onkologe (2007)
